8-K: Myomo Announces Final Medicare Fee Schedule Rates for MyoPro Devices

Myomo, Inc. has received final Medicare fee schedule payment rates for its MyoPro devices, effective April 1, 2024.

Summary

• Myomo, Inc. announced that the Centers for Medicare & Medicaid Services (CMS) has finalized the fee schedule payment rates for its MyoPro devices.
• The final average fee schedule rates for the Motion W device (L8701) is $33,480.90 and for the Motion G device (L8702) is $65,871.74.
• These rates will be effective starting April 1, 2024.
• The MyoPro was officially classified in the brace benefit category on January 1, 2024, allowing for lump sum reimbursement.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the successful finalization of reimbursement rates, which is a crucial step for the company's growth and market access.

Positives

• The finalization of the fee schedule rates is a significant milestone for Myomo.
• The new rates will enable Medicare Part B beneficiaries to access the MyoPro devices.
• The lump sum reimbursement model simplifies the payment process.
• The company has successfully concluded a process with CMS that began in 2018.

Risks

• The document does not explicitly mention any risks, but the company's future performance will depend on the adoption of the MyoPro devices at these reimbursement rates.
• There is a risk that the actual reimbursement amounts may vary based on individual circumstances and claims processing.

Future Outlook

The company anticipates that the new reimbursement rates will facilitate greater access to MyoPro devices for Medicare Part B beneficiaries, potentially increasing sales and revenue.

Management Comments

• Paul R. Gudonis, Myomo's Chairman and CEO, stated that they are extremely gratified to have reached a successful conclusion with CMS.
• He also noted that this is an important milestone for qualified Medicare Part B beneficiaries and for Myomo as a company.

Industry Context

This announcement is significant for the medical robotics industry, as it establishes a clear reimbursement pathway for advanced orthotic devices like the MyoPro. This could encourage further innovation and adoption of similar technologies.

Comparison to Industry Standards

• The reimbursement rates for MyoPro are specific to its unique technology and classification as a powered upper-limb orthosis.
• There are no direct comparables in terms of specific devices and reimbursement rates, as MyoPro is the only marketed device in the U.S. that uses EMG signals to restore upper limb function.
• However, the rates can be compared to other durable medical equipment reimbursements, which are generally lower, highlighting the advanced nature of the MyoPro technology.

Stakeholder Impact

• Shareholders are likely to view this announcement positively as it provides a clear path for revenue generation.
• Medicare Part B beneficiaries will have increased access to the MyoPro devices.
• The company's employees may benefit from increased job security and potential growth opportunities.

Next Steps

• Myomo will begin receiving reimbursements at the new rates starting April 1, 2024.
• The company will likely focus on increasing sales and adoption of the MyoPro devices among Medicare Part B beneficiaries.

Key Dates

Keywords

MyoPro, Medicare, CMS, DMEPOS, Reimbursement, Fee Schedule, Medical Robotics, Orthosis, L8701, L8702